Member Info for Moorscloud

Thinking about your clinical steps post HH, it can't be common for a small pharma to have 3 irons in the fire. Sorry for my ignorance but are they linked and is there a reason why Hemo have developed CAR-T first especially as CBX seems to be even more of a game-changer>

Most informative HH thanks: understanding rather better now Vlad's allusion to Microsoft!

Thanks JHFH / HH and if Hemo does even 5 bag, that is still only 10p a share and so eminently affordable.

And as about 5% going clinical do get all the way through to the market* with all the rewards that entails, a 20 to 1 shot seems pretty good odds and that's not accounting for all the scientific positives many posters here have been kind enough to detail.

* according to Lukas Bjorkland

Lund University School of Economics and Management

MOVING THROUGH THE CLINICAL PIPELINE

An event study on Biotech companies’ stock prices when shifting clinical

trial phases

This share (Reata) tripled in one day from $31 to $93 but any investor wishing to have a holding of ten thousand shares, would have to have paid out $331,000.

To get a holding of ten thousand shares in Hemogenyx, costs just £210.

Of course the risk profiles are different but is it wrong to think therefore that more people would be willing and able to invest in Hemo and that therefore Hemo could easily do better than triple on positive FDA news?

Bit snide Ht . Why is HH's informed and informative, cautious thoughtfulness upsetting you?

They-mogenyx soon then..?

Thank you MrJ and JHFH - nose clamped and opportunity clenched with both hands!

A newbie question if I may. When a company receives share-changing news which could presumably arrive at any time of day, is the company expected/obliged to inform shareholders instantly or can they wait to the following morning or even a few days later to release a 7am RNS?

I do not know enough to join JHFH in defending Vlad but I certainly feel the potentials behind his science warrant much more leeway than some seem willing to give him.

Why this wave of venom at Vlad now when the medical (and financial) wonders of his science are so close? A bit of (presumably meaningful) teasing seems a small price to pay.

JohnNth - wondered what you and other lth are expecting today?

What are you thinking?

TDD/JNth - thank you for these, my situation exactly too.

Boom boom

The Winner on their deathbed says "That was worth it."
The Loser on their deathbed says "Oh, if only...."

But can I ask, what if you're in Poly for dividends not growth?

Maybe sounds more like "Hang on in there, it'll be worth it!" than "Fabulous news tomorrow" but very happy either way!

JHFH - great summary, thank you. Having failed all 3 science subjects at school, understanding what the Hemo team has discovered with CAR-T and CBR is so far beyond me. I know from my own lymphoma consultant that CAR-T is being developed elsewhere as well but it sounds as though Hemo's CBR is unique and would be utterly game-changing. Could we really be in on the beginning of something so important?

Great analogy HfH - just a bit difficult for any passenger waiting anxiously, who bought lots of tickets to make sure of reaching the destination because they're heading towards the dentist for £12,000 of emergency implant treatment...

And ps - talking of lucky 7s, purely accidentally, that was today's 77th post!